Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology reports corporate, financial, and regulatory news as a biotechnology company focused primarily on unlocking the potential of its intellectual property. Company updates commonly address efforts to partner or out-license selected technologies, asset divestitures such as research-facility equipment and the C-CATHez catheter, and financial results that discuss operating expenses, cash resources, and capital needs.
News releases also cover Belgian transparency notifications, major shareholding thresholds, total voting rights, share counts, double voting rights, and warrants tied to the company’s Euronext-listed securities.
Summary not available.
Celyad Oncology (CYAD) received a Bid Price Notice from Nasdaq on April 19, 2023, indicating its American Depositary Shares (ADSs) were below the $1.00 minimum closing bid price for 30 consecutive business days. The Company has until October 16, 2023, to regain compliance by maintaining a price of at least $1.00 for ten consecutive days. If compliance is not achieved, the ADSs may be transferred to Nasdaq Capital Market or subjected to delisting. Additionally, on March 31, 2023, Celyad received a Stockholders’ Equity Notice from Nasdaq for not meeting the $10 million stockholders’ equity requirement, reporting approximately $4.6 million as of December 31, 2022. The Company has until May 15, 2023, to submit a compliance plan. Despite these notices, Celyad states that its business operations remain unaffected.
Celyad Oncology (Euronext & Nasdaq: CYAD) received a notice from Nasdaq on March 31, 2023, indicating it failed to meet the required stockholders' equity of $10 million. Celyad reported approximately $4.6 million in equity as of December 31, 2022. The company has until May 15, 2023, to submit a plan to regain compliance. Nasdaq may grant a 180-day extension if the plan is accepted. The letter does not immediately affect the listing or trading of Celyad's American Depositary Shares under the symbol CYAD.
Celyad Oncology (CYAD) announces the appointment of Georges Rawadi as the new CEO, effective March 23, 2023. Rawadi, a seasoned executive with 20+ years in pharma/biotech, has previously held significant roles within Celyad and other biotech firms. He will officially start on April 17, 2023, while Michel Lussier remains as Interim CEO until then. The Board has expressed confidence in Rawadi's leadership abilities and his expertise in CAR-T therapies to drive growth and development. Rawadi emphasizes his commitment to harnessing Celyad's intellectual property to overcome limitations in CAR-T approaches.
Celyad Oncology (CYAD) announced a shift in strategy focused on enhancing CAR-T therapies through its research on NKG2D, B7-H6, and shRNA platforms. The company reported a net loss of €40.9 million for 2022, an increase compared to €26.5 million in 2021, primarily due to a €35.1 million impairment of oncology intangible assets. As of December 31, 2022, Celyad had cash reserves of €12.4 million, projected to fund operations into Q4 2023, but anticipates needing additional financing within the next 12 months. Upcoming milestones include updates on research platforms and the introduction of a new CEO in 2023.
Celyad Oncology (Euronext & Nasdaq: CYAD) announced it will release its full year 2022 financial results on March 23, 2023. A conference call is scheduled for March 24, 2023, at 1 p.m. CET / 8 a.m. ET. Company management will discuss the results and provide updates on recent changes and milestones. Participants can join via various telephone options or access a live webcast. Celyad specializes in developing innovative CAR T-cell therapies. The company emphasizes its strategic model and the potential of its IP, while also highlighting risks including uncertainties about its ability to continue as a going concern and potential patent disputes.
Celyad Oncology (CYAD) announced a non-cash impairment of €20.5 million in goodwill and €35.1 million in consolidated intangible assets for the fiscal year ending December 31, 2022. This impairment results from a strategic shift emphasizing R&D and monetization of intellectual property due to uncertainty in deal flow. The company's net assets have fallen below half of its capital, prompting the Board to propose a business plan at the May 5, 2023 shareholders' meeting. An audit for fiscal year 2022 is still in process, with detailed results expected around March 23, 2023.
Celyad Oncology reported notable challenges in its 2022 operations, impacting its clinical development efforts. Key issues included insufficient efficacy results from the CYAD-211 program in the IMMUNICY-1 trial and serious adverse events in the CYAD-101 trial, prompting temporary suspensions. In response, the company implemented significant cost-cutting measures, executed a hiring freeze, and transferred employees to external partners to streamline operations. These transformations are projected to extend the cash runway until Q4 2023 without external financing. Celyad will now focus on enhancing its research and maximizing its intellectual property estate.
Celyad Oncology (NASDAQ: CYAD) faced significant challenges in 2022, leading to a strategic transformation. Clinical trials for its allogeneic CAR-T therapies, CYAD-211 and CYAD-101, encountered issues with efficacy and safety, resulting in a temporary suspension of trials. Consequently, the board decided to refocus on core assets and undergo organizational restructuring. Initiatives included cost-cutting measures, a hiring freeze, and asset sales. These actions are projected to extend the cash runway until Q4 2023. Looking ahead, the company aims to strengthen its research in NKG2D and B7-H6 platforms, optimize its intellectual property, and foster strategic collaborations.
Celyad Oncology faced significant challenges in 2022, including insufficient clinical efficacy in its allogeneic CAR-T programs, leading to a temporary suspension of trials. The company's board decided to focus on core assets and restructure its operations. Key measures included cost-cutting initiatives, a hiring freeze, and organizational transfers to ProPharma Group. These efforts are projected to extend the cash runway into Q4 2023. Celyad also initiated a reorganization under interim CEO Michel Lussier, concentrating on its research in NKG2D and B7-H6 while maximizing its intellectual property. The goal is to create shareholder value through strategic collaborations.